首页 工具
登录
购物车
Merimepodib

Merimepodib

产品编号 T3444   CAS 198821-22-6
别名: 美泊地布, VX-497, VI-21497

Merimepodib (VX-497) 是一种新型非竞争性肌苷一磷酸脱氢酶抑制剂,具有广谱抗病毒活性。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Merimepodib Chemical Structure
Merimepodib, CAS 198821-22-6
规格 价格/CNY 货期 数量
1 mg ¥ 393 现货
5 mg ¥ 938 现货
10 mg ¥ 1,490 现货
25 mg ¥ 2,780 现货
50 mg ¥ 3,970 现货
100 mg ¥ 5,790 现货
1 mL * 10 mM (in DMSO) ¥ 933 现货
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
重组蛋白限时优惠
Doxorubicin hydrochloride限时半价
产品目录号及名称: Merimepodib (T3444)
点击图片重新获取验证码
选择批次  
纯度: 99.31%
TargetMol batch loading
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Merimepodib (VX-497) is a novel noncompetitive inhibitor of Inosine monophosphate dehydrogenase(IMPDH).
体外活性 VX-497 has antiproliferative effect on lymphoid and keratinocyte cells. VX-497 (MW 452.5) is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM. The antiproliferative effect of VX-497 in cells is reversed within 48 h of its removal[1]. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC50s ranging from 6 to 19 μM. VX-497 is 100-fold more potent, with an IC50 of 380 nM and a corresponding CC50 of 5.2 μM, for a therapeutic index of 14. The antiviral activity of VX-497 in HepG2.2.2.15 cells is reversed threefold by the addition of guanosine[2].
体内活性 Oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, with an ED50 value of appr 30-35 mg/kg in mice. Single daily dosing of VX-497 is shown to be as effective as twice-daily dosing in this model of immune activation[1]. GVHD developed in the vehicle-treated allografted F1 mice and treatment with VX-497 improved all manifestations of the disease significantly. The 2.9-fold increase in spleen weight in allografted animals is reduced to a 1.6-fold increase in the VX-497-treated mice. Serum IFN-gamma levels are increased 54-fold in the vehicle group while there is a 7.4-fold increase in VX-497-treated animals[3].
细胞实验 The murine fibroblast L929 cell line is cultured in Eagle minimal essential medium supplemented with 10% fetal bovine serum, nonessential amino acids, 50 U of penicillin per mL, 50 μg of streptomycin per mL, and 2 mM?l-glutamine. EMCV is infected at 500 PFU/107?L929 cells. Cells are left untreated or are treated with different concentrations of murine IFN-α alone, VX-497 alone, or combinations thereof.
别名 美泊地布, VX-497, VI-21497
分子量 452.46
分子式 C23H24N4O6
CAS No. 198821-22-6

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 31 mg/mL (68.51 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2101 mL 11.0507 mL 22.1014 mL 55.2535 mL
5 mM 0.442 mL 2.2101 mL 4.4203 mL 11.0507 mL
10 mM 0.221 mL 1.1051 mL 2.2101 mL 5.5254 mL
20 mM 0.1105 mL 0.5525 mL 1.1051 mL 2.7627 mL
50 mM 0.0442 mL 0.221 mL 0.442 mL 1.1051 mL

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Jain J, et al. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37. 2. Markland W, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother. 2000 Apr;44(4):859-66. 3. Decker CJ, et al. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice. Drugs Exp Clin Res. 2001;27(3):89-95.
A939572 DHODH-IN-14 hDHODH-IN-4 NCT-503 JX06 Olutasidenib Sodium dichloroacetate ADH-1

相关化合物库

该产品包含在如下化合物库中:
抑制剂库 药物功能重定位化合物库 抗癌细胞代谢库 抗感染化合物库 抗代谢疾病化合物库 ReFRAME 相关化合物库 已知活性化合物库 共价抑制剂库 临床期小分子药物库 代谢化合物库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Merimepodib 198821-22-6 Immunology/Inflammation Metabolism Microbiology/Virology Proteases/Proteasome Dehydrogenase HCV Protease Antiviral HBV 美泊地布 HCV Inhibitor Hepatitis C virus Hepatitis B virus VX497 VX 497 inhibit MMPD VI 21497 VX-497 VI-21497 VI21497 inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼